SynDevRx Dec 2019 San Antonio Poster on Hyperglycemia Inhibition with PI3K
SynDevRx Dec 2019 San Antonio Poster on Hyperglycemia Inhibition with PI3K
SynDevRx Poster Dec 2019 SABCS Hyperglycemia PI3K
Metabo-Oncology: The Latest Frontier in Cancer Research
There is a new field of cancer research that is only just now starting to take shape but is promising to greatly increase our understanding of cancer and what can influence how it develops over time. This field is being called metabo-oncology.
SynDevRx launches Metabo-Oncology.com website
Metabo-Oncology press release 26Mar 2019 FINAL
SDX at AACR: Obesity confers immuno-suppressive tumor microenvironment – Poster Presentation
April 1, 8:00 AM to 12:00 PM 1226 / 4 – A novel polymer-conjugated methionine aminopeptidase 2 (MetAP2) inhibitor SDX-7320 inhibits the growth of EO771 mammary gland tumors and ameliorates the immunosuppressive tumor immune micro-environment (TIME)
Increasing cancer rates among young adults tied to obesity
Rates of six different cancers that are associated with obesity increased among adults ages 25-49 between 1995 and 2014, according to the research, which was published in the journal Lancet Public Health and based on information in the Cancer in North America database. These cancers include multiple myeloma, colorectal, endometrial, gallbladder, kidney and pancreatic.
Dr. Lewis Cantley, PhD on the role of insulin in PI3K resistance
Dr. Lewis Cantley discusses targeting the PI3K pathway in breast cancer and the importance of managing ambient insulin levels during therapy.
Tackling the Obesity and Cancer Epidemic (ASCO May 25, 2017)
Research is still lacking to support a link between obesity and an increased risk of developing all types of cancer. Nevertheless, a review1 of more than 1,000 epidemiologic studies by the International Agency for Research on Cancer (IARC), a division of the World Health Organization, examining the preventive effects of weight control on cancer risk […]